| Autor: |
Di Simone MP; Department of General Surgery and Transplants, University of Bologna, Bologna., Baldi F, Vasina V, Scorrano F, Bacci ML, Ferrieri A, Poggioli G |
| Jazyk: |
angličtina |
| Zdroj: |
Clinical and experimental gastroenterology [Clin Exp Gastroenterol] 2012; Vol. 5, pp. 103-7. Date of Electronic Publication: 2012 Jun 11. |
| DOI: |
10.2147/CEG.S31404 |
| Abstrakt: |
The aim of the present study was to assess the potential barrier effect of Esoxx(®), a new nonprescription medication under development for the relief of gastroesophageal reflux symptoms. Esoxx is based on a mixture of hyaluronic acid and chondroitin sulfate in a bioadhesive suspension of Lutrol(®) F 127 polymer (poloxamer 407) which facilitates the product adhesion on the esophageal mucosa. The mucosal damage was induced by 15 to 90 minutes of perfusion with an acidic solution (HCl, pH 1.47) with or without pepsin (2000 U/mL, acidified to pH 2; Sigma-Aldrich). Mucosal esophageal specimens were histologically evaluated and Evans blue dye solution was used to assess the permeability of the swine mucosa after the chemical injury. The results show that: (1) esophageal mucosal damage is related to the perfusion time and to the presence of pepsin, (2) mucosal damage is associated with an increased permeability, documented by an evident Evans blue staining, (3) perfusion with Esoxx is able to reduce the permeability of the injured mucosa, even after saline washing of the swine esophagus. These preliminary results support further clinical studies of Esoxx in the topical treatment of gastroesophageal reflux symptoms. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
